Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

MURA

Mural Oncology plc

Jul 05 • 04:00PM ET

2.97

Dollar change -0.03
Percentage change -1.00	%

Healthcare • Biotechnology • Ireland • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF VTWO VHT IWC DFAC VTWG VT MEDX BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	2.66%	Shs Outstand	16.69M	Perf Week	-3.26%
Market Cap	50.25M	Forward P/E	-	EPS next Y	-5.29	Insider Trans	0.00%	Shs Float	16.47M	Perf Month	-8.05%
Income	-	PEG	-	EPS next Q	-1.95	Inst Own	77.19%	Short Float	8.24%	Perf Quarter	-35.43%
Sales	-	P/S	-	EPS this Y	37.41%	Inst Trans	-	Short Ratio	6.67	Perf Half Y	-46.10%
Book/sh	13.88	P/B	0.21	EPS next Y	32.01%	ROA	-	Short Interest	1.36M	Perf Year	-
Cash/sh	13.69	P/C	0.22	EPS next 5Y	-	ROE	-	52W Range	2.95 - 17.00	Perf YTD	-49.83%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-82.53%	Beta	-
Dividend TTM	-	Quick Ratio	11.27	Sales past 5Y	6.94%	Gross Margin	-	52W Low	0.68%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	11.27	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	27.23	Volatility	5.08% 4.82%
Employees	117	Debt/Eq	0.06	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	36.76%	Payout	-	Rel Volume	0.74	Prev Close	3.00
Sales Surprise	-	EPS Surprise	30.83%	Sales Q/Q	-	Earnings	May 14 BMO	Avg Volume	203.42K	Price	2.97
SMA20	-8.05%	SMA50	-15.06%	SMA200	-29.15%	Trades		Volume	150,694	Change	-1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$15
Apr-04-24	Initiated	Morgan Stanley	Overweight	$13

Jul-02-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-05-24 04:15PM	Mural to Present and Host 1x1 Investor Meetings at the 14th Annual East Coast IDEAS Investor Conference (GlobeNewswire)
Jun-04-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.28%
May-23-24 05:00PM	Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-14-24 01:55PM	MURA Stock Earnings: Mural Oncology Reported Results for Q1 2024 (InvestorPlace)
07:00AM	Loading…
07:00AM	Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-03-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-24-24 04:00PM	Mural Oncology Announces Upcoming Presentation at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-09-24 04:00PM	Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Apr-04-24 04:00PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.87%
Mar-26-24 01:53PM	MURA Stock Earnings: Mural Oncology Reported Results for Q4 2023 (InvestorPlace)
07:00AM	Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-24 04:35PM	Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-04-24 04:15PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-24 07:00AM	Mural Oncology to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
04:30PM	Loading…
Feb-05-24 04:30PM	Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-24 07:00AM	Mural Oncology Announces Enhancements to Late-Stage Clinical Trials (GlobeNewswire)
Dec-18-23 11:52AM	MURA Stock Earnings: Mural Oncology Reported Results for Q3 2023 (InvestorPlace)

Mural Oncology Plc is a clinical-stage oncology company. It engages in the business of discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. The company was founded on May 31, 2017 and is headquartered in Dublin, Ireland.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MURA

Mural Oncology plc

Upgrade your FINVIZ experience